# Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents

> **NCT00111345** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University Hospital Muenster** · enrollment: 550 (actual)

## Conditions studied

- Myeloid Leukemia

## Interventions

- **DRUG:** Anthracyclines
- **DRUG:** liposomal daunorubicin
- **DRUG:** 2-CDA
- **DRUG:** AI

## Key facts

- **NCT ID:** NCT00111345
- **Lead sponsor:** University Hospital Muenster
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-03
- **Primary completion:** 2012-03
- **Final completion:** 2017-03
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2012-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111345, "Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00111345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*